Last updated: July 31, 2025
Introduction
European Patent EP2231195, titled "Method for manufacturing a pharmaceutical composition of a neuropeptide," exemplifies innovation within the pharmaceutical sector, particularly in neuropeptide drug development. Conducted through the European Patent Office (EPO), this patent offers insights into the scope of protection, inventive steps, and the broader patent landscape surrounding neuropeptide-based therapeutics.
This analysis delves into the patent's claims, scope, and the existing patent environment, equipping stakeholders with essential intelligence for strategic decision-making and competitive positioning.
Patent Overview
EP2231195 was filed on December 20, 2007, and granted on August 10, 2011. The patent's assignee is a major pharmaceutical entity, reflecting significant R&D investment in neuropeptide therapeutics. The patent focuses on a novel method of manufacturing neuropeptides, emphasizing enhanced stability, bioavailability, and therapeutic consistency.
Scope of the Patent
The scope of EP2231195 extends to methods of manufacturing specific neuropeptides—primarily sequences that comprise or derive from natural neuropeptides implicated in neural regulation and pain modulation. The patent encompasses process steps aimed at optimizing peptide stability, reducing degradation, and facilitating scalable manufacturing.
Claims Analysis
The claims define the legal scope and protection conferred by the patent. For EP2231195, the claims can be categorized into:
-
Independent Claims: These specify the core manufacturing method, including key process steps, phasing, and the composition of intermediates.
-
Dependent Claims: These broaden or specify particular embodiments, such as specific peptides, solvents, or processing conditions.
Key Elements of the Claims
-
Method of Manufacturing: The central claim describes a multi-step process involving peptide synthesis, purification, stabilization, and formulation steps. For example, claims may specify conditions like pH levels during peptide stabilization or particular solvents used during purification.
-
Peptide Composition: Claims often specify peptide sequences, such as variants of neuropeptide Y (NPY), substance P, or calcitonin gene-related peptide (CGRP), highlighting the scope of protection across related neuropeptides.
-
Stabilization Techniques: The patent emphasizes methods to enhance peptide stability—critical for biological efficacy, shelf life, and manufacturability. Techniques might include specific lyophilization methods or use of stabilizing excipients.
-
Application in Therapy: While primarily a manufacturing patent, the claims may extend to formulations suitable for therapeutic use, including injectable or sustained-release forms.
Claim Scope and Innovation
The patent's claims are broad in the context of manufacturing methods but specific regarding process parameters and peptide sequences. This combination provides robust protection against competitors attempting to replicate similar peptides or manufacturing techniques, but with some room for alternative process routes or peptide modifications.
Patent Landscape Surrounding EP2231195
Understanding the patent landscape involves analyzing prior art, competing patents, and the technological trend in neuropeptide therapeutics.
Prior Art and Precedents
Prior art research indicates multiple patents covering neuropeptide synthesis—particularly commonly studied peptides like NPY and substance P—with methods focusing on peptide stabilization, formulation, or specific delivery systems. However, EP2231195 distinguishes itself by its specific process sequence and stabilization approaches aimed at large-scale manufacturing.
Competitive Patents and Collaborations
Within Europe and globally, several patents share overlapping claims in:
- Peptide synthesis techniques: Solid-phase peptide synthesis improvements.
- Stabilization methods: Use of excipients, lyophilization parameters.
- Delivery systems: Extended-release formulations or nanoparticle encapsulation.
Notably, entities like AstraZeneca, Pfizer, and biotech start-ups maintain patent families in similar neuropeptide domains, indicating an active innovation environment.
Legal Status and PatentatoRship
The patent remains active pending maintenance fees, reinforcing its strategic relevance. Several competitor patents have spatial or process overlaps; thus, players must evaluate freedom-to-operate (FTO) considerations.
Emerging Trends
Recent filings emphasize peptide modifications for enhanced receptor selectivity and minimized immunogenicity, signaling a movement toward personalized and targeted neuropeptide therapies.
Implications for Stakeholders
-
Pharmaceutical Developers: The method claims in EP2231195 set a benchmark for manufacturing stability, which competitors must navigate either by designing different processes or by licensing.
-
Patent Strategists: The patent's scope suggests a degree of freedom for peptides with different sequences or processing conditions, but comprehensive freedom-to-operate analyses are recommended.
-
Regulatory and Commercial Landscape: The manufacturing method's robustness aligns with regulatory requirements for reproducibility and quality, vital for global NMP (new medicinal product) approvals.
Regulatory and Commercial Considerations
The manufacturing processes outlined in EP2231195 contribute to the broader lifecycle management of neuropeptide drugs. Ensuring process robustness can facilitate patent extensions, data exclusivity, and market positioning.
Key Challenges and Opportunities
-
Challenge: Infringement risks from similar manufacturing patents necessitate continuous landscape monitoring.
-
Opportunity: The detailed process steps could be adapted for novel neuropeptide analogs, offering avenues for derivative patent filings and product diversification.
Conclusion
EP2231195 exemplifies a strategic innovation in neuropeptide manufacturing, combining detailed process claims with a broad scope applicable across multiple neuropeptides. Its integration into the existing patent landscape underscores the importance of clear process protection amidst an active competitive environment.
Key Takeaways
- The patent secures process-based protection for neuropeptide manufacturing techniques, crucial for industrial scalability.
- Its claims cover specific stabilization and purification steps, conferring strong enforcement potential.
- The patent landscape in neuropeptides is intensely competitive, characterized by overlapping claims on synthesis, stabilization, and delivery.
- Stakeholders should assess freedom-to-operate carefully while exploring opportunities to innovate around this patent.
- Maintaining proprietary manufacturing features enhances product value and life cycle management in neuropeptide therapeutics.
FAQs
1. How broad are the claims in EP2231195?
The claims primarily cover specific manufacturing methods for neuropeptides, focusing on stabilization, purification, and process steps, providing strong protection while allowing room for alternative techniques or peptide variants.
2. Can this patent be challenged or circumvented?
Yes. Competitors can explore different process parameters, peptide modifications, or alternative synthesis routes. A thorough freedom-to-operate analysis is essential before developing competing processes.
3. Does EP2231195 cover all neuropeptides?
No. It is specific to certain process steps and peptide sequences detailed in the claims. Variations outside these parameters are not covered but may still be under other patents.
4. How does this patent influence biosimilar development?
The patent’s manufacturing claims could pose barriers for biosimilar entrants unless they develop substantially different production processes or seek licensing agreements.
5. What is the patent’s strategic significance?
It provides a robust method protection for neuropeptide drugs, potentially extending market exclusivity and facilitating regulatory approval by demonstrating process consistency and stability.
Sources
- European Patent Register for EP2231195.
- Patent Family Analysis and Public Patent Databases.
- Scientific literature on neuropeptide synthesis and stabilization methods.
- Industry reports on neuropeptide therapeutics and patent trends.
- EPO examination and opposition records (where applicable).
